Technosphere® Insulin System: MannKind’s lead investigational product candidate is currently in Phase 3 clinical trials in the U.S., Europe and Latin America, to study its safety and efficacy in the treatment of type 1 and type 2 diabetes. The therapy consists of a proprietary dry powder formulation of insulin that is inhaled into the deep lung using MedTone®, the company’s proprietary inhaler. Because the product has been found to produce a profile of insulin levels in the bloodstream that mimics the insulin profile normally seen in healthy individuals immediately following the beginning of the meal, researchers believe that the Technosphere® Insulin System may have the potential to change the way diabetes is treated. The potential use of insulin early in the progression of diabetes would represent a paradigm shift in the treatment of this disease and is currently be explored.Il mercato potenziale è enorme Paris-based Sanofi wants a wider slice of the $14 billionmarket for insulin products. Demand for the drugs is rising asobesity and lack of exercise boost the number of people withdiabetes. The chronic disease, which can lead to organ damage,affects 200 million people worldwide, and cases may double by2025, according to the World Health Organization.I players sul mercato sono Sanofi e Eli LillySanofi-Aventis SA's long-actinginsulin Lantus is easier to use than U.S. rival Eli Lilly & Co.'sproduct Humalog in controlling blood-sugar levels, according to astudy sponsored by the French drugmaker. Both products have similar effectiveness. Patients preferredglargine, or Lantus, which is injected once a day, rather thanshots three times a day with short-acting lispro, or Humalog,said lead researcher Reinhard Bretzel from the Justus-LiebigUniversitaet in Giessen, Germany, in the study published in theLancet. ``We conclude that insulin glargine provides a simple andeffective option that is more satisfactory to patients than islispro for early initiation of insulin therapy, since it wasassociated with a lower risk of hypoglycemia, fewer injections,less blood glucose self monitoring, and greater patientsatisfaction, than was insulin lispro,'' Bretzel wrote. Lantus is a long-acting synthetic form of human insulin, thehormone that controls sugar in the blood. Sanofi is trying toshow that Lantus may reduce some drawbacks associated withconventional insulin preparations including weight gain andhypoglycemia, an abnormal decrease of blood-sugar level. Sanofi rose 74 euro cents, or 1.6 percent, to 47.78 euros asof 9:27 a.m. in Paris trading. The shares have declined 24percent this year.
Mannkind (Mnkd.n) current price 6.3
Technosphere® Insulin System: MannKind’s lead investigational product candidate is currently in Phase 3 clinical trials in the U.S., Europe and Latin America, to study its safety and efficacy in the treatment of type 1 and type 2 diabetes. The therapy consists of a proprietary dry powder formulation of insulin that is inhaled into the deep lung using MedTone®, the company’s proprietary inhaler. Because the product has been found to produce a profile of insulin levels in the bloodstream that mimics the insulin profile normally seen in healthy individuals immediately following the beginning of the meal, researchers believe that the Technosphere® Insulin System may have the potential to change the way diabetes is treated. The potential use of insulin early in the progression of diabetes would represent a paradigm shift in the treatment of this disease and is currently be explored.Il mercato potenziale è enorme Paris-based Sanofi wants a wider slice of the $14 billionmarket for insulin products. Demand for the drugs is rising asobesity and lack of exercise boost the number of people withdiabetes. The chronic disease, which can lead to organ damage,affects 200 million people worldwide, and cases may double by2025, according to the World Health Organization.I players sul mercato sono Sanofi e Eli LillySanofi-Aventis SA's long-actinginsulin Lantus is easier to use than U.S. rival Eli Lilly & Co.'sproduct Humalog in controlling blood-sugar levels, according to astudy sponsored by the French drugmaker. Both products have similar effectiveness. Patients preferredglargine, or Lantus, which is injected once a day, rather thanshots three times a day with short-acting lispro, or Humalog,said lead researcher Reinhard Bretzel from the Justus-LiebigUniversitaet in Giessen, Germany, in the study published in theLancet. ``We conclude that insulin glargine provides a simple andeffective option that is more satisfactory to patients than islispro for early initiation of insulin therapy, since it wasassociated with a lower risk of hypoglycemia, fewer injections,less blood glucose self monitoring, and greater patientsatisfaction, than was insulin lispro,'' Bretzel wrote. Lantus is a long-acting synthetic form of human insulin, thehormone that controls sugar in the blood. Sanofi is trying toshow that Lantus may reduce some drawbacks associated withconventional insulin preparations including weight gain andhypoglycemia, an abnormal decrease of blood-sugar level. Sanofi rose 74 euro cents, or 1.6 percent, to 47.78 euros asof 9:27 a.m. in Paris trading. The shares have declined 24percent this year.